Urban Poling Supports VeDA’s International Balance Awareness Week

Urban Poling is proud to continue its long-standing partnership with the Vestibular Disorders Association (VeDA), a collaboration that has lasted for over four years. Our Activator® Poles have been widely recognized and used by the balance community in many countries, offering additional support and confidence to individuals whose mobility and quality of life are severely restricted by balance disorders. VeDA’s work and resources have been crucial for those seeking guidance and support, and we are honored to help raise awareness for their important mission.

Starting on September 15th, the International Balance Awareness Week will begin, and we are excited to join forces with VeDA and encourage others to participate in this global event. Together, we can raise awareness of the challenges faced by individuals with balance disorders, and of the vital resources VeDA provides to help this growing community.

To learn how you can get involved in Balance Awareness Week, visit VeDA’s official page.

For those interested in trying Urban Poling’s Activator® Poles, which offer greater stability and mobility, visit VeDA’s partner page, where special discounts are available.

About Urban Poling Inc.
Urban Poling Inc. is a Canadian company and a global leader in the promotion of fitness and rehabilitation through pole walking. Known for its innovative Activator® Poles, Urban Poling focuses on improving mobility, stability, and overall quality of life for individuals with balance disorders, neurological conditions, and those in post-surgical rehabilitation. The company’s products and programs are recommended by leading healthcare professionals worldwide, and Urban Poling Inc is dedicated to empowering people of all ages to live active, healthy lifestyles.

About the Vestibular Disorders Association (VeDA)
The Vestibular Disorders Association (VeDA) is the leading international organization dedicated to supporting individuals with vestibular disorders. Since its founding in 1983, VeDA has provided patients, caregivers, and healthcare professionals with essential resources, education, and advocacy to improve the diagnosis and treatment of vestibular disorders. VeDA aims to reduce the diagnostic journey for individuals with dizziness, vertigo, and imbalance, and help improve their quality of life through support and guidance.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version